Darren Cline serves as Chief Commercial Officer at Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological disorders. In this role, he leads the company's commercial strategy, including market access, launch planning, and global commercialization efforts for its pipeline, notably the epilepsy treatment candidate XEN1101. With over 25 years of experience in the pharmaceutical industry, Cline brings deep expertise in rare diseases, neurology, and psychiatry, positioning Xenon for successful product launches and sustained growth. Prior to joining Xenon in 2023, Cline was Executive Vice President and Chief Commercial Officer at Neurocrine Biosciences, where he spearheaded the launch and commercialization of INGREZZA (valbenazine), the first FDA-approved treatment for tardive dyskinesia, achieving blockbuster status with peak annual sales exceeding $2 billion. Under his leadership, Neurocrine expanded into additional indications like chorea associated with Huntington's disease. Earlier in his career, he held senior commercial roles at Jazz Pharmaceuticals as Senior Vice President of Marketing and Sales, driving the growth of Xyrem for narcolepsy, and at UCB Pharma, where he managed U.S. commercial operations for epilepsy and neurology portfolios. Cline's track record of building high-performing commercial teams and navigating complex payer environments has earned him recognition as a leader in biotech commercialization. A graduate of the University of California, Irvine, he holds an MBA from the University of San Diego. At Xenon, he is instrumental in preparing for potential near-term approvals and building a robust commercial infrastructure to deliver transformative therapies to patients with unmet needs in neurology.